• E Garrido, J Botella de Maglia, and O Castillo.
• Servicio de Hipobaria y Fisiología Biomédica, Universidad de Barcelona, L'Hospitalet de Llobregat, Barcelona, España; Instituto de Estudios de Medicina de Montaña (IEMM), Barcelona, España. Electronic address: eduardogarrido@movistar.es.
• Rev Clin Esp. 2020 Mar 17.

AbstractMore than 100 million people ascend to high mountainous areas worldwide every year. At nonextreme altitudes (<5500 m), 10-85% of these individuals are affected by acute mountain sickness, the most common disease induced by mild-moderate hypobaric hypoxia. Approximately 140 million individuals live permanently at heights of 2500-5500 m, and up to 10% of them are affected by the subacute form of mountain sickness (high-altitude pulmonary hypertension) or the chronic form (Monge's disease), the latter of which is especially common in Andean ethnicities. This review presents the most relevant general concepts of these 3 clinical variants, which can be incapacitating and can result in complications and become life-threatening. Proper prevention, diagnosis, treatment and management of these conditions in a hostile environment such as high mountains are therefore essential.Copyright © 2020 Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI). All rights reserved.

12 keywords...

hide…